Access to data and to skills specific to AI are among the key challenges pharma companies face to unlock the technology’s ...

Latent Labs has raised $50 million of new funding as it commercialises its GenAI technology for designing new proteins for ...

Researchers have applied AI and machine learning to every stage of the drug development process. This includes identifying targets in the body, screening potential candidates, designing drug ...

The potential of using artificial intelligence in drug discovery and development has sparked both excitement and skepticism among scientists, investors, and the general public. Researchers have ...

The energy component—and cost—associated with artificial intelligence should not be overlooked in all the excitement.

One of the pillars of modern medicine is the life-saving drugs that pharmaceutical companies spend years developing to cure ...

Nature Medicine has been chronicling advances in medical technology and health care. To mark the journal’s 30th anniversary, each month ...

Isomorphic Labs, a spin-off from DeepMind, is applying AI-first principles to drug discovery rather than just protein ...

focusing on AI and cybernetics in drug development. Phase I involved aligning AI-driven processes with Conduit’s goals, validating proprietary inputs, and analyzing cocrystal candidates.

The company is developing generative AI methods to design proteins from scratch, with applications in drug discovery and ...

Is China setting the global standard for AI-driven drug development? DeepSeek, a relatively unknown AI firm based in Hangzhou, China, shocked the industry last week with claims that its technology ...